Recursion Pharmaceuticals (RXRX) Appoints Namandjé Bumpus and Elaine Sun to its Board Mar 18, 2025 08:03AM
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun Mar 18, 2025 08:00AM
Dynavax to Report Third Quarter 2024 Financial Results and Host Conference Call on November 7, 2024 Oct 24, 2024 04:10PM
Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 Jul 23, 2024 04:00PM
Dynavax to Present at Upcoming Investor Conferences May 28, 2024 04:18PM


Apr 24, 2024 04:05PM Dynavax to Report First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
Feb 27, 2024 06:54PM Dynavax to Present at TD Cowen's 44th Annual Health Care Conference
Feb 8, 2024 04:15PM Dynavax to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 22, 2024
Jan 3, 2024 06:33PM Dynavax to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Nov 20, 2023 05:04PM Dynavax to Present at the 6th Annual Evercore ISI HealthCONx Conference
Oct 26, 2023 04:15PM Dynavax to Report Third Quarter 2023 Financial Results and Host Conference Call on November 2, 2023
Oct 19, 2023 01:15PM Dynavax to Present at the H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
Sep 6, 2023 04:05PM Dynavax to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 3, 2023 04:05PM Dynavax Reports Second Quarter 2023 Financial Results and Raises Full Year Revenue Guidance
Jul 20, 2023 04:15PM Dynavax to Report Second Quarter 2023 Financial Results and Host Conference Call on August 3, 2023
May 30, 2023 04:15PM Dynavax to Present at Upcoming Investor Conferences
May 8, 2023 04:15PM Dynavax to Present at the JMP Securities Life Sciences Conference
May 2, 2023 04:05PM Dynavax Reports First Quarter 2023 Financial Results
Apr 18, 2023 04:15PM Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023
Mar 1, 2023 04:15PM Dynavax to Present at the Cowen 43rd Annual Health Care Conference
Jan 15, 2023 07:00PM Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
Jan 15, 2023 07:00PM Clover Provides Updates on COVID-19 Vaccine Commercial Launch and Strategic Priorities in 2023
Nov 30, 2022 05:27AM Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
Nov 30, 2022 05:27AM Clover’s Vaccine Candidate Reduced Household Transmission of SARS-CoV-2 in Study Published in Clinical Infectious Diseases
Oct 9, 2022 08:12AM Clover Provides Update on 2022 Corporate Milestones
Oct 9, 2022 08:12AM Clover Provides Update on 2022 Corporate Milestones
Sep 20, 2022 04:43AM Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate
Sep 20, 2022 04:43AM Clover’s COVID-19 Vaccine Candidate Receives European Union GMP Certificate
Sep 19, 2022 07:42PM Clover’s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine
Sep 19, 2022 07:42PM Clover’s Universal COVID-19 Booster Vaccine Candidate Demonstrates Superior Neutralization of Omicron BA.5 Compared to Inactivated Vaccine
Sep 5, 2022 07:17PM Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine
Sep 5, 2022 07:17PM Clover’s COVID-19 Vaccine Candidate Demonstrates Superior Booster Responses Compared to Inactivated Vaccine
Aug 29, 2022 07:42PM Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
Aug 29, 2022 07:42PM Clover’s COVID-19 Booster Vaccine Candidate Demonstrates Robust Neutralization of Dominant Omicron BA.5
Aug 25, 2022 06:23AM Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
Aug 25, 2022 06:23AM Clover Announces Positive Phase 2/3 Results in Adolescents for its COVID-19 Vaccine
Sep 22, 2021 06:56AM Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
Jul 6, 2021 08:00AM Dynavax and Biological E Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Biological E's COVID-19 Vaccine Candidate
Nov 16, 2020 06:04AM Dynavax (DVAX), Biological E. Limited & Baylor College of Medicine Begin Phase I/II Clinical Trial of its COVID-19 Vaccine Candidate
Nov 16, 2020 06:00AM Biological E. Limited Starts Phase I/II Clinical Trial of its COVID-19 Vaccine Candidate
Jul 16, 2020 08:42AM Dynavax (DVAX) Enters Collaboration with Mount Sinai to Develop Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant
Jul 16, 2020 08:40AM Dynavax and Mount Sinai Announce Collaboration to Develop a Universal Influenza Vaccine Candidate with CpG 1018 Adjuvant
Mar 2, 2020 09:24AM Pre-Open Stock Movers 03/02: (FTSV) (TRIL) (TWTR) Higher; (BIOC) (ENLV) (NVAX) Lower (more...)
Jan 8, 2019 09:13AM Dynavax (DVAX) Reports Collaboration with Sam's Club to Make HEPLISAV-B Available to Sam's Club Patients
Jan 8, 2019 09:00AM Sam’s Club and Dynavax Technologies Corporation Announce Collaboration to Make HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted] Available to Sam’s Club Patients
Jan 22, 2018 09:29AM Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
Jun 21, 2017 08:30AM Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance
Nov 14, 2016 09:24AM Pre-Open Stock Movers 11/14: (CRBP) (HAR) (DGII) (MENT) Higher; (DVAX) (HEAR) (ACM) Lower (more...)
Apr 27, 2016 09:28AM Pre-Open Stock Movers 04/27: (SPA) (DWA) (WNC) Higher; (DVAX) (TWTR) (BWLD) Lower (more...)
Jun 1, 2015 08:30AM Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies